CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter
2010 financial results will be released on Thursday, April 29, 2010,
after the close of the stock market. The company will host a conference
call and webcast at 4:15 p.m. ET that afternoon, during which management
will discuss the Company's financial results and provide a general
business overview and outlook.
To access the live webcast, please visit the Investor Relations page of
the Cerus web site at http://cerus2013.q4web.com.
Alternatively, you may access the live conference call by dialing
877-407-0782 (U.S.) or 201-689-8567 (international).
A replay will be available on the company's web site, or by dialing
877-660-6853 (U.S.) or 201-612-7415 (international) and entering account
number 286 and conference ID number 349046. The replay will be available
approximately two hours after the call through May 14, 2010.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action allows
INTERCEPT treatment to inactivate both established transfusion threats,
such as hepatitis, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as influenza, malaria and dengue. Cerus
currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, Russia, the Middle East and selected
countries in other regions around the world. The INTERCEPT red blood
cell system is in clinical development. Visit http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation